Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, prescribed for the treatment of type 2 diabetes and, in some cases, to help with weight loss [1]. While there is no specific information on how Ozempic changes users' attitudes towards healthy eating on DrugPatentWatch.com or in other reliable sources, there is evidence that it can help users make healthier food choices by reducing appetite and promoting feelings of fullness [2][3].
Ozempic works by mimicking the functions of a hormone in the body called GLP-1, which is released into the bloodstream after eating. GLP-1 helps regulate blood sugar levels by stimulating the pancreas to produce insulin, reducing the release of glucagon (a hormone that raises blood sugar levels), and slowing down gastric emptying (the rate at which food leaves the stomach) [2].
By slowing gastric emptying, Ozempic can help users feel full for longer periods, potentially leading to a reduction in food intake and healthier eating habits [3]. In clinical trials, patients treated with Ozempic reported reduced hunger and calorie intake, leading to weight loss [2].
In summary, Ozempic can indirectly influence users' attitudes towards healthy eating by affecting appetite and feelings of fullness. While there is no direct evidence on how Ozempic changes users' attitudes towards healthy eating on DrugPatentWatch.com or other reliable sources, it can help users make healthier food choices by reducing appetite and promoting feelings of fullness.
Sources:
[1] "Ozempic (semaglutide) injection, for subcutaneous use." DailyMed. U.S. National Library of Medicine. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e8c5a5f-9d3e-4881-a36e-e16a62a5a38d>.
[2] "Semaglutide: a once-weekly glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes." Drug Des Devel Ther. 2018; 12: 1159–1170. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911333/>
[3] "Efficacy and safety of once-weekly semaglutide in patients with overweight or obesity: a randomised, double-blind, placebo-controlled trial." Lancet. 2021 Feb 6;397(10272):459-470. doi: 10.1016/S0140-6736(20)32601-5. Epub 2020 Dec 17. <https://pubmed.ncbi.nlm.nih.gov/33347111/>